GHK-Cu vs Adrenomedullin
Head-to-head comparison of GHK-Cu and Adrenomedullin for research applications. Both peptides are studied for various research applications, but they differ significantly in mechanism, evidence level, and dosing protocols.
Side-by-Side Comparison
| Attribute | Ghk Cu | Adrenomedullin |
|---|---|---|
| Category | Skin & Tissue Repair | Cardiovascular / Vasoactive |
| Mechanism | GHK-Cu chelates copper(II) ions via its histidine residue and delivers bioavailable copper directly to cells, preventing free copper oxidative damage. | Adrenomedullin signals through the calcitonin receptor-like receptor (CLR) complexed with receptor activity-modifying protein 2 or 3 (RAMP2/RAMP3), forming the AM1 and AM2 receptors respectively. |
| Evidence Rating | F — No Regulatory Activity | D — Biomarker / Early Research |
| Clinical Status | Available in cosmetic formulations; no drug approval | Research stage. MR-proADM used as prognostic biomarker in sepsis and heart failure. No approved therapeutic use of adrenomedullin peptide. |
| Safety Profile | Safety profile is excellent with minimal side effects reported in decades of cosmetic use and clinical research (PMID: 29986520); Topical forms are generally well-tolerated; mild skin irritation rare and typically limited to very sensitive skin | No human safety data from controlled therapeutic trials; Experimental IV infusion in healthy volunteers caused hypotension and reflex tachycardia |
| Route | Subcutaneous, Topical (cream/serum), or Intradermal (microneedling) | Intravenous infusion (research only) |
| Dose Range | SC: 50–200 mcg/day; Topical: 1–4% cream or serum applied to target area | 10–50 ng/kg/min in human physiological studies |
| Frequency | SC: Once daily; Topical: 1–2x daily | Continuous or bolus infusion |
| Molecular Weight | ~403.9 g/mol | ~6028 g/mol |
| Half-Life | ~30 minutes plasma | ~22 minutes (plasma) |
Overview
GHK-Cu and Adrenomedullin are both research peptides studied across multiple applications. This comparison examines their mechanisms, evidence base, dosing protocols, and safety profiles to help researchers understand the key differences and overlaps.
GHK-Cu — Mechanism & Evidence
GHK-Cu is a naturally occurring copper-binding tripeptide (glycyl-L-histidyl-L-lysine) found in human plasma, saliva, and urine. First discovered by Dr. Loren Pickart in 1973, plasma levels average 200 ng/mL at age 20 but decline to ~80 ng/mL by age 60. It has been extensively studied for wound healing, collagen synthesis, skin regeneration, and gene modulation, with decades of cosmetic use and a broad safety profile. Molecular weight is approximately 340 g/mol (as the copper complex), with the formula C14H24N6O4Cu.
Key claims: Improves skin firmness and elasticity; Promotes wound healing; Reduces fine lines and wrinkles.
GHK-Cu 50mg
50mg
Tesamorelin 10mg
10mg
Adrenomedullin — Mechanism & Evidence
Adrenomedullin is a 52-amino-acid vasodilatory peptide (MW ~6028 g/mol) originally isolated from human pheochromocytoma tissue. It is widely expressed in the cardiovascular system, lungs, kidneys, and adrenal glands, with potent vasodilatory, natriuretic, and cardioprotective properties. It is currently investigated as a biomarker (MR-proADM) for sepsis and heart failure prognosis, with no approved therapeutic use of the peptide itself.
Key claims: MR-proADM is a strong prognostic biomarker in sepsis; MR-proADM predicts mortality in acute heart failure; Adrenomedullin has potent vasodilatory effects in humans.
Shared Research Applications
These peptides target different research areas. GHK-Cu focuses on Skin Health, Anti-Aging, Wound Healing, while Adrenomedullin targets Sepsis Prognostication, Heart Failure Biomarker, Cardiovascular Research.
Safety Considerations
GHK-Cu: Safety profile is excellent with minimal side effects reported in decades of cosmetic use and clinical research (PMID: 29986520) Topical forms are generally well-tolerated; mild skin irritation rare and typically limited to very sensitive skin Injectable forms: mild injection site reactions, lightheadedness, nausea, flu-like symptoms possible; rotate injection sites to reduce local irritation
Adrenomedullin: No human safety data from controlled therapeutic trials Experimental IV infusion in healthy volunteers caused hypotension and reflex tachycardia Theoretical risk of excessive vasodilation and hemodynamic instability
Shop Research Peptides
GHK-Cu 50mg
50mg
Tesamorelin 10mg
10mg
BPC-157 5mg
5mg
Retatrutide 20mg
20mg
Retatrutide 10mg
10mg
BPC-157 10mg
10mg
Tirzepatide 10mg
10mg
Quality Documentation
Review batch documentation before making research purchasing decisions. Volta pairs product education with COA literacy so researchers can evaluate purity, identity, lot details, and testing context.
Product cards on this page link to current catalog entries and available quality documentation.
Related Research News
GHK-Cu in Research: Reconstitution, Stability, and Handling Guide
This guide covers the essentials of working with GHK-Cu in a research setting, from reconstitution math and solvent choice to stability and purity considerations. Learn how to handle copper peptides correctly and what to verify before starting a study.
GHK-Cu and Hair Follicle Growth: A Review of Copper Peptide Dermatological Research
Explore the preclinical evidence on GHK-Cu for hair follicle growth, including proposed mechanisms and research limitations.
Synergistic Regeneration: BPC-157, Thymosin Beta-4, and GHK-Cu in Healing Research
Explore the synergistic potential of BPC-157, Thymosin Beta-4, and GHK-Cu in regenerative research. Preclinical evidence and mechanisms reviewed.